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          Curcumin is a carotenoid natural product isolated from the rhizome 
of the plant Curcuma longa.  Among its many biological effects, 
curcumin has anti-inflammatory, anti-infective, and anti-cancer activity.  
The anti-cancer activity of curcumin has been studied extensively.   
      Angiogenesis plays a pivotal role in the metastasis of cancer: 
curcumin showed excellent anti-angiogenesis activity on metastatic 
tumors.  Several curcumin analogues have been synthesized and studied, 
and their biological activity was reported in the literature. One class of 
potent analogues are aromatic enones. In Dr Bowen’s laboratory sixty 
three compounds were synthesized and in the laboratory of Dr Jack 
Arbizer (Emory University, Atlanta, GA) they were tested for their anti-
angiogenic activity with an SVR endothelial cell growth assay developed 
by Dr Arbizer. The precise mechanism or the specific biological target on 
which these analogs exert their inhibition potential as anti-angiogenic 
agents is unknown. Therefore, structure-based molecular modeling is not 
a possibility. However, ligand based molecular modeling methods are 
available for studying and predicting which compounds among the sixty 
three can be further optimized for selectivity and desired property.  
 
 
            Computational studies were carried out to identify which 
structural features within the series of analogues are significantly 
important for activity. Initially, pharmacophore modeling was carried out 
in Molecular Operating Environment (MOE) software to identify the 
Interaction Pharmacophore Elements (IPE) and their relative geometry in 
three-dimensional space. Two different three dimensional quantitative 
structural Activity Relationship (3D-QSAR) studies, Comparative 
Molecular Field Analysis (CoMFA), and Comparative Molecular 
Similarity Indices Analysis (CoMSIA) were carried out with this dataset.  
SYBYL (versions 7.2 and 7.3) were used for the development of the 
models. Forty six compounds were used as the calibration or the training 
set. The model yielded a cross validated q2 of 0.289 for CoMFA and 
0.146 for CoMSIA analyses.  Eleven compounds were used as the test set 
(or the prediction) set to externally validate the QSAR models and their 
robustness. The predictions of the model are acceptable with a few 
outliers. 
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GLOSSARY OF TERMS 
 
Metastasis: The migration of cancer or tumor cells from the primary site 
of origin to random locations of the body via the blood or the lymphatic 
tissue to produce a secondary cancer growth. 
VEGF: vascular endothelial growth factor. 
bFGF: basic fibroblast growth factor. 
MMPs: matrix metalloproteinases. 
RI-QSAR: Receptor independent quantitative structural activity 
relationship study. 
RD-QSAR: Receptor dependent quantitative structural activity 
relationship study. 
Pharmacophore: Pharmacophore is defined as the three dimensional 
models of essential structural features of congeneric molecules that are 
necessary for biological activity. 
Descriptors: Descriptors are the independent variables in a QSAR study. 
They provide information of molecules that can be correlated to their 
biological affinity in a QSAR or QSPR (Quantitative structural property 
relationship) study. 
 
 iv
Force fields:  Force fields are the energy functions of a microscopic 
system of particles (molecules). They indicate the total potential energy 
possessed by the specific system of atoms or molecules. 
Dataset: Data set is defined as the biological affinity data of a congeneric 
series used in developing a quantitative structure activity correlationship 
studies. 
Training set:  Training set is defined as the set of compounds in a dataset 
used to develop a QSAR model. 
Test set (Predictive set): Test sets are the compounds used to externally 
validate the predictive property of a developed QSAR model. 
Dependent variables:  These are the biological affinity or biological 
response produced by the compounds of the dataset. 
Independent variables:  These are the molecular properties of the 
compounds. These are also called as descriptors in QSAR analysis. 
Biological affinity:  It is the biological response produced by the 
compounds in the assay. 
Predicted values:  These are the biological activity predictions of the 
QSAR model.  
Actual (Experimental) values: These are the experimentally reported 
biological affinity data used in developing the structure biological 
correlation analysis. 
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Residuals:  Residuals are the difference between the experimental values 
and the predicted biological activity values in a QSAR model. 
Biological Affinity - ED50 :  The amount of compound (concentration) 
that can produce a response in 50 % of the population. 
LD50 :  The concentration of the compound that can produce a lethal 
effect in 50% of the population 
Ki:  The concentration of the compound that inhibits the enzyme 
completely in an enzyme catalyzed reaction. 
ADME properties:  Absorption, distribution, metabolism, and excretion 
are the pharmacokinetic parameters of drug like compounds. 
CoMFA:  Comparative molecular field analysis. 
COMSIA:  Comparative molecular similarity index analysis. 
MSS:  Molecular spread sheet. 
PCA:  Principal component analysis. 
PLS:  Partial least squares regression. 
SAMPLS:  Samples distance partial least squares; Regression analysis. 
P:  Inhibition potential (LD50, ED50, Ki) 
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CHAPTER I 
BACKGROUND INFORMATION - CANCER 
 
              Among the subspecialties of internal medicine, medical 
oncology is an important frontier which has gained attention from various 
research communities.  Cancer and its associated ailments are second 
only to cardiovascular diseases that lead to death of an individual.  
Demographical evidence shows one in every six deaths are caused by 
some type of cancer.1  The mortality rate of cancer patients is usually 
high (65%).  Appropriate therapeutic approaches are crucial factors in 
cancer treatment.  Therapeutic approaches undertaken depend on the type 
of cancer, its pathological stage, and the condition of the patient.  
Primarily there are three treatment methods for cancer:2 (a) Invasive 
methods e.g., surgical removal of cancer tissue (surgical oncology); (b) 
Irradiation methods, which involve the use of high energy radiation, (c) 
chemotherapy, which involve the administration of toxic drugs.  Surgical 
methods are the most effective approaches since the bulk of the tumor 
tissue can be removed.  Surgical removal of a mass is an option 
applicable for solid tumors and also for tumors that have not yet 
 1
metastasized.  Metastasis is defined as the migration of the cancer cells 
from the primary region of origin to other parts of the body via blood and 
the lymphatic tissue.  Usually, additional surgery is not an option if the 
tumor is in the vital organs such as the heart, lungs, nervous tissue, and 
kidneys. 
 
        Radiation therapy is an effective method as it can selectively destroy 
the tumor cells with minimal effects with surrounding tissue. Radiation 
therapy kills cancer cells directly or indirectly by inducing apoptosis 
(programmed cell death). Surgical and radiation therapy are the effective 
methods for a complete “cure” if the tumor is still benign and has not yet 
transformed to a metastatic form. Radiation therapy uses high energy 
radiation; usually the source is a radioactive decaying isotope. 
 
        Chemotherapy is the most widely used and effective method for the 
treatment of cancer, as metastasis is not a limiting factor in 
chemotherapy. There are various classes of drugs that target cancer cell 
growth and division. These chemotherapeutic agents exert their 
therapeutic action by hampering the nucleic acid metabolism of the cell 
directly or indirectly. These include (a) drugs that inhibit the synthesis of 
precursors for nucleic acid synthesis (antimetabolites); (b) drugs that 
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interfere with the replication of DNA (alkylating agents and DNA 
intercalating agents); (c) drugs that inhibit various enzymes in nucleic 
acid metabolism; (e) drugs that inhibits the formation of mitotic spindles 
during cell division. 
 
Alkylating agents 
       These are the most widely used chemotherapeutic agents that were 
used to treat cancer in the 1960’s and 1970’s. They undergo activation to 
form strong electrophiles3. These electrophilic intermediates are attacked 
by nucleophilic groups such as hydroxyl, sulfhydryl, phosphate, amino, 
carboxyl, and imidazole groups of nucleic acids.  The chemotherapeutic 
effects of these are due to alkylation of DNA.  Alkylation occurs at the 
nucleophilic center of guanine (7th nitrogen position in guanine is the 
most nucleophilic atom) of the DNA strand. These alkylating agents are 
either monofunctional or bifunctional.  In addition to the guanine, other 
nitrogens in purine and pyrimidine bases of DNA are also involved as 
nucleophiles. The 1st and 3rd nitrogen of adenine, 3rd nitrogen of 
cytosine, and the 6th oxygen of guanine are the nucleophilic centers. 
 
        Nitrogen mustards were the first alkylating agents used in the early 
days of cancer chemotherapy. The below mentioned are some of the 
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widely used nitrogen mustards: mechlorethamine, cyclophosphamide, 
ifosfamide, melphalan and chlorambucil. The other classes of alkylating 
agents are dacarbazine, methylnitrosoureas (MNU): streptozocin, 
carmustine, lomustine, semustine and chlorozotocin.  some are prodrugs, 
e.g. cyclophosphamide. 
 
Antimetabolites-folic acid analogs 
        Folic acid is a precursor for nucleotide synthesis. Antimetabolites 
are a class of antineoplastic agents that inhibit the enzyme that catalyze 
the biosynthesis of nucleotides. These are the building blocks of nucleic 
acids, so inhibition of nuclei acid synthesis can retard cell division. 
Antimetabolites have structural resemblance with folic acid; they 
competitively inhibit the enzyme dihydrofolate reductase, which is a 
pivotal enzyme in nuclei acid metabolism. 
 The structures of the aforementioned agents are some of the most widely 
used anticancer drugs that act by the mechanism of DNA alkylation. 
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Fig 1.1.  Antimetabolite (folate analogue) methotrexate. The compound 
has a structural resemblance to PABA ( para amino benzoic acid ), which 
is a natural precursor of folic acid and eventually depletes nucleotides in 
the cell. 
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Miscellaneous anti-cancer agents 
        There are miscellaneous drugs that act at various stages of the cell 
cycle.  They include antibiotics, DNA intercalating agents, and drugs that 
inhibit the formation of mitotic spindles formation during cell division. 
The drugs in this category are taxol and cis-platin. 
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CHAPTER II 
TUMOR ANGIOGENESIS AND CANCER 
 
              It is imperative for living cells to obtain nutrients, oxygen, and 
essential metabolites for their normal sustenance and growth.  The 
diffusion limit for cells to acquire any of these nutrients is 100-200 
micrometers, so any further beyond this point requires a direct blood 
supply.4  To render these vital necessities, cells recruit new blood vessels 
in the form of rudimentary endothelial cell based capillaries.  This 
phenomenon is termed as vasculogenesis and angiogenesis. Angiogenesis 
is defined as the development of new rudimentary blood vessels in the 
form of capillaries from pre-existing vasculature. Angiogenesis is a 
phenomenon normally observed in several disease states like arthritis, 
corneal ulceration, proliferative retinopathy5, and tumors.  
 
            It is a well known fact that cancer cells divide at a faster rate and 
possess a higher metabolic rate than normal cells. Cancer cells promote 
angiogenesis via numerous biochemical messengers. Tumors can grow up 
to a certain mass (few microns in diameter) without direct vascular 
supply, but beyond this critical mass, tumors require direct blood vessels 
 9
for their survival and reproduction. This forces the tumor directly to 
stimulate angiogenesis from preexisting surrounding blood vessels. 
 
                   Angiogenesis is observed as a normal phenomenon only in 
the physiological cases of embryonic development and morphogenesis, 
during wound healing, and in tissue regeneration. Pathological and 
pathophysiological angiogenesis is a hallmark of various aliments and 
diseases (eg. stroke, ischemic heart diseases, and rheumatoid arthritis). As 
evident from the above information, angiogenesis is a predetermining 
phenomenon for the survival and progression of a variety of solid tumors. 
J Folkman et al was the first to propose this hypothesis.5 Thus, 
therapeutic intervention of the multiple targets that promote angiogenesis 
can significantly retard or completely inhibit angiogenesis and eventually 
suppress cancer growth by indirectly cutting off the supply of various 
necessities for normal cell growth. 
 
          Angiogenesis is a complex phenomenon, and the biochemical 
mechanisms that control it are delicate in nature. Angiogenesis is 
controlled by a sensitive physiological switch, which is triggered either 
by proangiogenic factors or antiangiogenic factors. These angiogenic 
factors are diverse in their function and broadly distributed both in 
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intracellular and extracellular environments. In normal tissues 
antiangiogenic factors predominant over proangiogenic factors. The most 
prominent proangiogenic factors are VEGF (vascular endothelial growth 
factor), bFGF (basic fibroblast growth factor), MMPs (Matrix 
metalloproteinases), cyclo-oxygenase - 2 (COX-2).6  the antiangiogenic 
factors are VEGFR-1, VEGFR-2, vasostatin, and endostatin. 
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CHAPTER III 
THERAPEUTIC PROPERTIES OF CURCUMIN 
 
             Curcuma longa L is a tropical herb usually seen in Southeast 
Asia. Since medieval times, the herb was reported in the literature for its 
various therapeutic effects.  The curative property was attributed to the 
yellow pigment constituent in the rhizome of the plant.  This active 
principle is curcumin (diferuloyl methane).  Curcumin has a broad range 
of therapeutic properties.  In recent times in vitro studies of curcumin and 
its various synthetic analogues demonstrated several and diverse 
categories of biological activity, especially anti-inflammatory (Crohn’s 
disease, arthritis, and several disorder of the cardiovascular system) and 
antimetastatic-antiangiogenic (anticancer potential and several other 
miscellaneous diseases).  In addition to the above, it also has anti-oxidant, 
anti-viral, and anti-infective activity.  Curcumin with its antioxidant and 
anti-inflammatory activity has invaluable therapeutic advantages.  
Experimental studies have demonstrated that curcumin is a potent 
scavenger of reactive oxygen species, which include superoxide anion 
radical and hydroxyl radical.7 Various pathophysiogical effects of 
curcumin at the cellular level include: induction of apoptosis 
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(programmed cell death) in cancer cell lines through downregulation of 
proangiogenic genes mediated by transcription factor NF-kB8 and IKB 
kinase, consequently.  Arrest cancer cell growth in S, G2 and M phases of 
the cell cycle.8  Northern blot analysis indicates a time dependent down 
regulation of VEGF and angiopoietin; these two targets are the most 
potent stimulators of angiogenesis.  With the above mentioned basis of 
anticancer potential and potent antiangiogenic property against various 
biological targets.  Curcumin and several synthetic analogs of curcumin 
were studied extensively.  Inhibition of arachidonic acid metabolism is 
the most prominent feature of curcumin in cellular system.  Arachidonic 
acid is also a key promoter of carcinogenesis in living systems. 
 
          A significant role of curcumin is its suppression of metastasis and 
the progression of solid tumors.  Curcumin has been shown to inhibit the 
differentiation of human umbilical vein endothelial cells (HUVEC).9  It 
also inhibits bFGF - induced corneal neovascularization in the mouse 
corneal. This phenomenon was discovered by Arbiser et al., and 
curcumin was considered as a promising lead candidate in biomedical 
research.  So, several curcumin analogs were synthesized and tested for 
anticancer and angiostatic activity by various research groups using 
several bioassays with different cell lines. 
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          Bioactivity studies have shown that various curcumin analogs are 
angiogenesis inhibitors, as observed in the chorioallantoic membrane 
assay. These inhibitory activities of curcumin analogues are due to 
reduction in the activity of vascular endothelial growth factor (VEGF) 
and matrix metalloproteinases (MMPs). Matrix metalloproteinases play a 
major role in cell membrane restructuring and consequently facilitate 
angiogenesis. 
 
           There are several biochemical mediators that promote cancer 
progression. The biological activity of curcumin can be attributed to the 
ways it affects various modulators of cellular and subcellular receptors  
(EGFR  and HER2), transcription factors (NF-kB , AP-1, Egr-1, beta 
catenin, and PPAR-γ), and various inflammatory mediating enzymes like 
cyclooxygenase (COX-2), 5-lipoxygenase, nitric oxidase synthase 
(iNOS), cyclin protein D1p, and cytokines (TNF, IL-6, IL-1 and  
chemokines). The biological activity of curcumin was attributed to the 
electrophilic property of the β diketone linker.10
  
          With these diverse bioactivity profiles, curcumin is considered a 
potential natural product lead for structure optimization in drug 
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discovery. But its poor solubility, undesired pharmacokinetic-
pharmacodynamic profile, and the lack of selectivity towards a single 
target limits its utility.  Structural modifications of curcumin analogs are 
an available alternative.  Novel analogs may be designed through in silico 
methods, synthesized, and subsequently tested for their biological affinity 
towards a single biological target of intent.  Curcumin is a benchmark 
reference. 
 
Molecular features of curcumin 
                 Curcumin exists in keto-enol tautomeric form, characteristic of 
1,3 carbonyl systems and there is intramolecular hydrogen bonding 
present in the molecule. The herbal extract of Curcuma longa has three 
fractions: curcumin (77%), demethoxycurcumin (17%), and 
Bisdemethoxycurcumin (3%). The later two are collectively called 
curcuminoids. The central β-diketone linker is an essential 
pharmacophoric feature for biological activity, and the two aromatic 
groups attached to the linker can be structurally modified for desired 
pharmacokinetic factors and selective biological affinity.  
 15
 
                                    Structure of curcumin  
 
 
 
 
 B 
               Fig 3.1. Three regions of curcumin: A and C are regions 
accommodating aromatic systems, and region B is the diketone linker.  
 
The following are the therapeutic activities of curcumin/turmeric; 
Antioxidant activity, anti-inflammatory, enhance wound healing, 
immunomodulatory, antispasmodic activity, antifungal, antiparasitic and 
antibacterial activity, antimutagenic, antimetastatic, and antiangiogenic 
activity. 
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CHAPTER IV 
QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP  
(QSAR) STUDIES 
                                      
         In silico molecular modeling methods are extremely useful in the 
biomedical sciences.  Fundamentally, molecular modeling methods are 
classified into structure - based or structure - dependent and ligand - 
based or structure - independent methods.  Here, structure refers to the 
biological target (receptor, enzyme, nucleic acid, ion channel, or carrier 
protein). QSAR analysis, pharmacophore modeling, putative receptor 
modeling, and consecutive search query fall in the later class of molecular 
modeling methods.  The predictions of these ligand based methods are 
pivotal in making critical decisions in future analog synthesis.  
 
          The primary intent of this thesis is to develop a three - dimensional 
QSAR model of experimentally validated compounds (curcumin analogs) 
as anti-angiogenesis agents.  The QSAR model development and its 
predictions are used to develop synthetic targets of potentially active 
compounds. Presumably, this will significantly reduce research time and 
expenses.  A QSAR, in general, may be a reliable tool when structural 
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information of the biological target is unknown – i.e., has not been 
characterized by X - ray crystallography or by NMR methods.  When the 
drug - receptor structural details are available however, it can yield more 
realistic picture which in turn, leads to robust computational models with 
higher probability for activity prediction. 
 
          Microscopic characteristics of matter are important for compounds 
possessing biological activity.  In biological systems, these properties are 
the results of the constituent atomic composition and arrangements within 
the molecules. Most biomolecules, natural ligands, and drug-like 
molecules usually interact with their biological target through non 
covalent molecular forces. These Interactions are usually shape 
dependent. Non-covalent interactions fundamentally depend on the 
magnitude of steric and electrostatic forces. Computational drug 
designing strategies are fundamentally classified into two methods: (a) 
structure (receptor)-based molecular modeling methods, and (b) ligand - 
based molecular modeling methods.  When the biological structural data 
(receptors, ion channels, enzymes, or Nucleic acids) are available, 
transition state analog design, docking studies or molecular dynamic 
simulation studies can provide an in-depth picture of the interaction of the 
active ligand with the interacting elements in the active domain of the 
biological target.  The prerequisite for drug-like molecules is to have high 
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affinity at the active site of the biological target when compared to the 
natural ligand.  It has been postulated that the pharmacodynamic activity 
is achieved through drug-receptor binding with subsequent 
conformational changes in the drug receptor complex, which results in a 
cascade of biological events leading to the observed physiological 
change.  This is achieved when the affinity for a drug like molecule is 
higher than the natural ligand in a biological system. 
 
         When the biological structure data are unknown, structure-activity 
correlation studies with statistical methods can provide information 
regarding the characteristics of the putative target/receptor.  Structure-
activity relationship studies (SAR), de novo ligand design, and semi-
empirical calculation methods are some of the other alternative 
approaches used in ligand design.  Several computational methods are 
used to develop structure-property relationships (QSPR).  QSAR 
empirical studies are one of the extensive methods used to predict 
structure-property co-relations of bioactive molecules.  In the drug 
discovery process various properties (e.g. physicochemical, quantitative 
structure property relationship (QSPR), pharmacokinetic and 
toxicological) are important.  Quantitative structure toxicity relationship 
(QSTR) are to be evaluated collectively with an intention to develop a 
successful clinical candidate.  A QSAR study can be undertaken to 
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predict any of the above mentioned properties.  These structure-property 
correlationship studies are pivotal in the drug discovery pipeline.  QSAR 
studies provide an invaluable tool for identifying the important structural 
features required for activity, and eventually a computational tool for lead 
optimization. 
 
           Minor changes in the constituents of the molecules, functional 
groups changes, or alternation in geometry can affect biological activity: 
stereo chemical properties in a molecule for a series of structural 
congeners can profoundly affect biological activity. Three-dimensional 
quantitative structure activity relationship (QSAR) analyses can provide 
an in-depth analysis based on two most likely interaction forces: steric 
and electrostatic. 
 
            When biological activity for a series of molecules which differ in 
their structural features is observed, empirical methods like docking, 
scoring, and structure property or structure activity relationships can be 
used.   QSAR in a pharmacodynamic perspective is a statistical corelation 
method between molecular properties and their corresponding biological 
activity in vitro or in vivo.  This approach has the potential to predict for a 
wide range of properties (e.g., water solubility, lipophilicity, partition 
function and biological affinity).  Also, QSAR aids in differentiating 
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drug-like molecule from non drug-like molecules based on toxicicity 
predictions, drug metabolism, and ADME properties, as well as drug 
deposition in the tissue.   
 
           The vast majority of target specific drugs fall in either one of the 
following categories: organic small molecules, nucleotides, 
oligosaccharides, peptides, or proteins.  The most significant properties of 
these are steric (shape and volume) and electronic (electrostatic potential 
and electric charge).  The above mentioned two are the major properties 
of drug-like molecules for their affinity towards their biological target.               
 
           A dataset of a homologous series of molecules (target specific 
ligand or molecules) that has biological affinity towards a specific target 
can be modeled to predict the properties of unknown molecules.  QSAR 
studies were first developed by Hanch and Fujita.11   The proposed study 
was based on substitution constants.  These quantitative structural-
activity relationship studies are based on how the property is being 
affected as a function of the substitution groups in a series of congeners.  
These substituent constants are hydrophobic constants (π), Hammett 
constants (σ), and molar refractivity (MR).  The hydrophobicity constant 
(π) provides information of the logarithm of the partition constant (logP) 
of a substituted molecule relative to an unsubstituted molecule. The 
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hydrophobicity constant is an indicator of the non-polar/polar nature of 
the substituent.   The Hammett constant σ is an indicator of electron-
donating or electron-withdrawing effects of the substituent.  It is derived 
from the ionization constant of acids, and the substituent present in the 
acid molecule.   Molar refractivity is an indicator of polarisability of the 
substituent on the molecule, and it is derived from the Lorentz-Lorentz 
equation.  This equation is a function of density and molecular weight of 
the compound and its refractive index.  QSAR studies can be feasible 
with the above methods when there is a similar motif with the principle 
structure and few substituents.  When there is structural diversity and 
increased three dimensional conformations.  QSAR analysis with the 
above mentioned constants become a difficult task to try to correlate 
structure with bioactivity.  Even though correlation can be achieved, 
validation of the results is a difficult task.  Later the two-dimensional 
QSAR methods were developed, which are based on the topographical 
indices, but these methods were also found to have some drawbacks.                
 
           Three-dimensional QSAR methods are becoming the most 
extensively used QSAR methods in property prediction in biological 
systems, as well as in toxicological studies.  As mentioned before, the 
interaction is dependent on the three-dimension arrangement of groups in 
the molecule.  The independent variables used in QSAR studies are the 
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indicators of the microscopic properties of molecules.  These can either 
be derived or calculated by quantum mechanical methods.  These 
independent molecular information rich variables are termed as 
descriptors.  Descriptors provide information of the molecules and how it 
affects their physicochemical properties.  
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CHAPTER V 
DESCRIPTORS IN QSAR STUDIES 
 
           Descriptors are information rich variables defining molecules.  
Descriptors are grouped in two categories: (a) whole molecules 
descriptors, and (b) fragment descriptors.  Whole molecule descriptors 
are indicator properties of the entire molecule itself (e.g., molecular 
weight, molar refractivity).  Fragment descriptors are calculated based on 
the constituent atoms or substituent functional groups of the molecule.  
Substituent constants like the hydrophobicity constant (π) and the 
Hammett constant (σ) fall in this category.   
 
         Molecular descriptors can be calculated by computational methods. 
Currently, molecular descriptors are calculated readily with currently 
available computer hardware and computational software.  Fragment 
based descriptors are independent of the configuration and the three-
dimensional confirmation of the molecules.  They are not as information 
rich when compared to whole molecule descriptors.  Whole molecule 
descriptors are efficient and widely used descriptors, as they provide 
information of three- dimensional properties of molecules. 
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          The classic whole molecule descriptor is clogP, which is the 
octanol-water partition function.  Partition of drug molecules through the 
biological membrane into the cell is an important factor to exert its 
biological activity. Other three-dimensional descriptors are derived from 
molecular fields i.e.,  steric and electrostatic fields. 
 
           Judicious selection of descriptors or a group of descriptors is 
critical for the intended QSAR analysis and property prediction.  
Descriptor selection is based on the information content and its degree of 
relevance to the QSAR study.  Some descriptors provide desired results 
for one QSAR property prediction, while other types of descriptors are 
useful for different types of property predictions. There is some 
interdependency between descriptors, so when they are used as 
independent variables in a QSAR study they yield similar results.  Thus, 
an appropriate selection of descriptors is an important factor.  Poor 
selection of descriptors yields inefficient QSAR models or even gives 
misleading predictions.  Selections of many descriptors are to be avoided 
as they might tend to over fit the model.  This can be due to chance 
correlations because many descriptors were tried in developing the 
model.  Chance correlation is a major setback in QSAR model 
development. To avoid chance correlation, variable selection methods 
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through genetic algorithms and progressive scrambling are carried out.  
This can avoid the potential problem to some extent.  But the modeler is 
to be always wary of these factors during QSAR model building. 
 
       QSAR method based on Comparative Molecular Field Analysis – 
CoMFA and Comparative Molecular Similarity Indices Analysis – 
CoMSIA  
           Biomolecules interact significantly through steric and electrostatic 
forces, so it is obvious to use descriptors derived from these two 
contributing fields in the QSAR model development. Based on this 
hypothesis, comparative field analysis (CoMFA) and comparative 
molecular similarity indices analysis (COMSIA) QSAR methods were 
developed.  First, CoMFA analysis was developed for a series of steroid 
and their binding affinity towards carrier proteins by Richard D.  Cramer 
et al.12 This work laid the foundation for computational studies in which 
shape (three-dimension arrangement of atom or groups in a molecule) can 
significantly affect their affinity to a biological target.  Three-dimensional 
QSAR studies based on the CoMFA method or alternative methods are 
considered to be reliable for property predictions of unknown 
compounds. 
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          There exists a relationship between molecular structure and 
biological affinity: BA (eg.,  Ki, IC50, LD50, ED50). This biological 
response is expressed as Log (1/BA) = f (x1, x2, x3, ………xN). The 
descriptor variables, x1, x2, x3,…………xN (steric and electrostatic fields) 
are determined by PLS (Partial least squares) analysis. 
 
          Three-dimensional QSAR methods based on CoMFA have some 
inherit inconsistencies that can affect the final predictive property of the 
model. They were addressed later by Gerhard Klebe et al.13 His research 
group implemented similarity indices as descriptors in three-dimensional 
QSAR model development. This formalism of the QSAR model 
development is termed as comparative molecular similarity analysis 
(CoMSIA).  This method is more successful than its predecessor CoMFA 
based QSAR models.  The important drawback of CoMFA is its steep 
region shift; the magnitude of Lennard-Jones and Coulomb potentials 
change is high and increases as the sampling is performed from the outer 
regions towards the center of the molecule.  To avoid this steeper region 
shift in the QSAR model development, cut-off values are used for 
Lennard-Jones potential (steric fields) and the Coulomb potential 
(electrostatic fields) calculation in the CoMFA based QSAR model.  
Actually the regions inside the molecules have some information rich 
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descriptors.  Potential E(r) is inversely proportional to the distance (r) 
from the center of the molecule. CoMFA used Lennard-Jones and 
Columbic potentials in the calculation of the descriptors while CoMSIA 
uses Gaussian approximation in calculating similarity indices at various 
grid points. 
 
          The protocol for developing a three-dimensional QSAR model is 
similar in both CoMFA and CoMSIA.    
 
Three-dimensional QSAR analysis based on CoMSIA and its 
advantages over CoMFA  
    
          CoMSIA analysis uses sampling of similarity indices at various 
grid points of the common alignment of molecules in the dataset.  This 
sampling is performed at all the equally spaced grid points of the defined 
lattice.  These lattice points are present inside and outside the molecule. 
In CoMFA analysis the lattice points located inside the molecules are not 
taken into account in the statistical correlation analysis.  For example in 
PLS analysis15  there is a cut-off value defined before the PLS run is 
carried out.  This cut-off value is assigned to avoid field values that are 
very high in magnitude. But in a CoMSIA analysis, the lattice points 
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present inside and outside the molecule are taken into account.  The 
potentials at the lattice points are the independent variables used in PLS 
analysis.  CoMSIA has five different property fields.  These five different 
fields are used to significantly evaluate the property and partition them 
spatially in different locations of the molecule.  This, in turn, signifies 
which property plays a critical role in their contribution to the affinity or 
binding of the molecule to the receptor. It has significant importance in 
several steps of lead optimization when diverse properties of drug 
molecules are taken into account.  
 
Designing the calibration set or training set 
          In any QSAR method the fundamental basis for developing the 
model is universal.  There should be a statistical correlation between the 
dependent variable and the independent variables (descriptors). These 
relationships are either linear or nonlinear in nature. The dependent 
variable is usually the biological affinity (Ki, IC50, LD50 and ED50), which 
is converted to Log10 (1/activity): pED and pKi. A QSAR analysis is 
usually carried out in two steps.  
 
          The first step is to develop a model that describes the 
correlationship between the independent and dependent variables, which 
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is defined as this function: y = f(x).  The relationship is expressed as a 
function, and this defines how the dependent variable (y) is affected by 
the independent variables (x), the molecular descriptors.  The training set 
model parameters are called regression coefficients or sensitivities.  The 
later step is to derive independent variables from one or more samples 
and the sensitivities from the model.  
 
          In step two the derived independent variables from the training set 
are used to predict the dependent variables (biological affinity).  This 
prediction is performed with the test set or the prediction set.  This is the 
reason why the initially chosen dataset is divided into two groups: 
calibration set (or training set) and prediction set (or the test set). 
 
         The training set is used to develop the QSAR model, and the test set 
is used to validate the model externally and also to predict the degree of 
accuracy of the model. The robustness of the model depends on the 
predictable properties of the model.  The dataset should be large enough 
with the diversity in the structural congeners and their corresponding 
range of biological activity to be meaningful. The training set compounds 
are usually higher in number than the test set. The dividing of the training 
set and the test set is based on random picking of the compounds and 
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classifying them into the training set and the predictive or test set.  The 
selection of training set and test set is done taking into account the 
structural diversity in both the datasets and the corresponding range of 
biological activity of the molecules.  
 
 Three-dimensional QSAR method based on CoMFA and CoMSIA 
analysis are performed with the following protocol 
 
1) Structural input via sketching the molecule in the computer 
program followed by energy minimization, and calculation of 
mathematical descriptor is carried out. The later is the essential 
property of the molecule in three-dimensions.  One should take 
into account which descriptor is efficient in structure property 
correlation studies. 
2) The molecules of the dataset are aligned so that they have a 
common three-dimensional orientation.  Alignment is usually 
carried with atom fit or field fit alignment methods in Sybyl.  
Several modifications can be carried out (changing the 
stereochemistry, modifying the torsion in the common backbone).  
Alignment in carried out in a manner to yield the least possible 
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(RMS) root mean square deviation between the common points 
chosen in aligning.  
3) An evenly spaced (step size) lattice on the superimposed 
alignment is defined.  The dimensions of the grid are with a little 
extension in all the three x, y, z - cartesian co-ordinates so that it 
accommodates all the molecules. Usually the grid spacing of the 
lattice is 2 Å; however, the grid dimensions and the spacing can 
be modified if the superimposed molecules are to be rotated or 
translated in the grid.  The step size or spacing of the lattice can be 
modified to 1.5 Å or 1 Å.  This is observed with a penalty of 
increased computational time in developing the model as the 
number of PLS sampling points increase exponentially in the 
lattice. 
4) The magnitude of the steric (van der W’aals) and electrostatic 
fields (Columbic with a distance dependent dielectric-1/r2) at all 
the lattice points are calculated.  The steric and electrostatic 
interactions are determined with a probe atom (sp3 hybridized 
carbon atom with a unit positive charge). 
5) A molecular spread sheet is created with the dataset. Converting 
the dependent variable, biological affinity (IC50, LD50, ED50, Ki) 
 32
to Inverse logarithm values (1/biological activity) and entering the 
data as the dependent variable in the QSAR analysis is required.  
6) The columns are created with the independent variable (CoMFA           
columns and CoMSIA Indices as per the analysis whether it is 
CoMFA or CoMSIA). 
7) Statistical correlation analysis is carried out in a sequential 
manner with leave-one-out PLS method first.  This is done to 
identify the optimum number of components to derive the best 
model.  Then these optimum number of components are used in 
cross-validation to predict the q2   (average r2).  The cross validated 
correlation coefficient q2 falls in the range from 0 to 1.  For really 
good predictable models, the cross validated q2   is in the range of 
approximately 0.4 and higher. The final step is the no-validation 
PLS method. 
8) The last step is simultaneously predicting the dependent variables 
of both the training set and the test set. 
9) Residuals or errors for the compounds in the QSAR model 
(training set and test set compounds) are determined. Residual or 
errors of prediction are calculated as follows: Residuals = 
experimental activity – predicted activity. 
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10) The scattered plots of predicted vs experimental or actual 
dependent variable (biological affinity) are generated.  If the 
model is reliable, there is a positive correlation and most of the 
data points are pretty close to the 450  diagonal in the scattered 
plot; however, there usually will be some outliers in the model. 
11) With the magnitude of residuals in the scattered plots, compounds 
that are highly predicted and outliers can be observed in the 
model. 
12) After eliminating the outliers, the QSAR models are derived in an 
iterative manner to check the improvement of predictions of the 
model. Elimination of too many outliers can result in a propensity 
for a biased model. 
13) The final step is the validation of the QSAR model.  This is the 
external validation of the model with the compounds of the test 
set.  The predictions of the QSAR model are interpreted as stereo 
contour coefficient maps. Compounds with good predictions by 
the model are placed in the contour coefficient maps. Now the 
favorable and disfavorable interactions of different field 
contributions, which are represented as contour maps are 
observed. These maps provide insights into any structural 
modifications in the different regions of the compounds (addition 
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or elimination of electrostatic - charged groups, steric - bulky 
groups, H - bond donor or H - bond acceptor) and may be inferred 
with stereo view of the contour maps. 
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CHAPTER IV 
HYPOTHESIS AND EXPERIMENTAL DESIGN 
 
          The primary focus of this thesis is to develop a three-dimensional 
QSAR model based on CoMFA fields and COMSIA indices as descriptors. 
Since the structural information of the biological target is neither available 
in the SVR cell growth assay nor reported in literature elsewhere, ligand 
based modeling is the only method to develop a computational model for 
the prediction of potent curcumin analogs.  This study should be able to 
pave the way for further research towards the synthesis of new molecules.                  
 
           Based on whether there is structural information available or not, 
QSAR studies can be carried out by two methods: (1) It can be either 
structure independent or (2) structure dependent.  For the former, the 
biological target structure is not considered directly in developing the 
QSAR model.  The later approach, however, includes structural details of 
the biological target into account when developing the model.  In this 
research study, the precise biological target on which curcumin acts is not 
certain; therefore, the structure independent QSAR methods were 
employed in developing the model. 
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          Three-dimensional QSAR methods are most widely used to predict 
new chemical entities in silico which can possibly have improved 
biological activity.  The Sybyl19 (versions 7.2 and 7.3) molecular modeling 
software was used as the modeling tools in developing the QSAR model 
(based on CoMFA fields and COMSIA indices as descriptors).  The 
computational methods employed in this research are entirely structure 
independent methods.  The dataset of curcumin analogs aromatic enones 
with their corresponding biological activity was determined via the SVR 
assay and previously reported.18
 
Details of experimental assay data: Dataset 
          The endothelial cell proliferation assay was developed Dr Jack 
Arbiser et al at Harvard medical school.16  Based on this experimental 
evidence of in vitro SVR cell growth assay of curcumin, curcumin’s 
biological activity can be attributed to the inhibition of basic Fibroblast 
growth factor (bFGF) whose effects are shown to inhibit endothelial cell 
proliferation and angiogenesis in vivo.6  With this evidence, various 
structural analogues were explored for biological activity.  Curcumin has 
three distinct molecular regions: the two aromatic systems (R1 and R2) 
and the central hepta-1,6-dien-3,5-dione linker.  Several structural 
analogues of curcumin were designed and synthesized.  The 
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corresponding SVR assay was carried out with all the aromatic enones.  
There is a significant increase in potency observed with these 
compounds.  The inhibition potential ranged from 0 to 100 %.  These 
aromatic enones have a central linker, this linker is abridged to an enone 
system instead of having hepta-1,6-dien-3,5-dione linker found in 
curcumin.  This is followed by the substitution on the aromatic system 
with various substituent groups R1 and R2 or with heterocyclic aromatic 
systems.  The aromatic enones curcumin analogs were designed and 
synthesized in the Bowen research laboratory at the University of 
Georgia. Some of the compounds may have been obtained commercially, 
if available at that time. 
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                                         Fig 6.1.  Curcumin 
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Fig 6.2.  The three regions of curcumin A and C form the Aromatic 
systems and C the β - diketone linker.17     
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  Fig 6.3. Curcumin structure and the abridged aromatic enone parent 
Analog. X==X represent various cyclic linkers.17 R represent various 
substituents on the two aromatic systems A’ and C’ respectively. 
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          The in vitro SVR assays of the sixty three aromatic enone analogs 
were carried out at Emory University School of Medicine.  The assay is a 
cell based assay with 10,000 murine cells/well in a 24 well cell culture 
dish. Initially the cells were incubated with 10 % DMEM (1ml/well) 
under CO2 atmosphere.  During the 24 hrs incubation period, the cells 
adhere to the bottom of the surface.  After the 24 hrs period the media 
was replaced again with a 10 % DMEM media.  Simultaneously all the 
sixty three compounds were dissolved in the least amount of 
dimethylsulfoxide, DMSO, to prepare a stock solution of 10 µg/ml, with 
appropriate dilution concentrations of 1 µg/ml, 3 µg/ml, 6 µg/ml, or 9 
µg/ml.  The cultures were later incubated for 48 hrs, and the cells were 
washed. The number of cells per well was determined with Beckman 
Coulter Z1 cell and particle counter, and the percentage inhibition was 
calculated.  Finally this percentage inhibition was reported at three 
different concentrations of 1 µg/ml, 3µg/ml, and 6µg/ml for each 
compound. 
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CHAPTER VII 
MOLECULAR MODELING AND COMPUTATIONAL DETAILS 
 
           Many of the aromatic enone antiangiogenic agents used in the 
dataset have been published.18  The dataset consists of sixty three 
compounds and their corresponding biological activity.  The biological 
affinity as measured by percent inhibition ranges from 0 to 100% was 
experimentally determined for all the sixty three compounds at three 
different concentrations (1µg/ml, 3µg/ml and 6µg/ml).  These compounds 
were evaluated in the SVR cell growth assay as discussed in chapter 6.  
The SVR assay was termed after the cell lines used in the assay.  SVR is 
designated for Immortalized endothelial cell.  In the development of the 
QSAR model, the dataset was grouped into calibration or training sets 
consists of 46 compounds, and the prediction or test set or predictive set 
of 11 compounds. 
 
 Structure sketching and alignment 
          All the structures were sketched with the cleanup options available 
in Sybyl 7.2 of Tripos Inc.19  Gasteiger-Huckel partial charges were 
calculated for all the molecules.  Energy minimization was carried out 
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with the following minimization parameters to produces a local minima 
conformation of each molecule. 
Force field:  Tripos force field20 was used in the energy minimization of 
every molecule. 
Charge:  Gasteiger-Huckel partial charges are calculated for all the 
molecules in the dataset.  Distance dependent dielectric constant (1/r) = 1 
is used in calculating the interaction fields at various lattice points.  
Conjugated gradient method was used in energy minimization with 5000 
minimization iterations. Step size of  0.005 kcal/mole was set in the 
process. 
 
            The energy minimization was carried out with a 0.005 kcal/mole 
gradient step size with conjugated gradient as the termination method.  
The numbers of iterations used were 5000.  This energy minimization 
yielded the local minima for the molecules.  All the molecules were 
named as (Cur_1, Cur_2, Cur_3,…………….Cur_63).  A database 
named CurALIGN40.mdb was created with these compounds. 
 
 
 
Database alignment 
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            The next step is the alignment of molecules of the dataset: 
database. Alignment is achieved taking into criteria of the co-ordinates of 
the molecules that render the final common alignment with least root 
mean squares (RMS) deviation in the common groups or atoms used in 
aligning the cogeneric series.  Typically, the alignment of the compounds 
for QSAR studies is usually performed by three methods.21 
1) Bioactive conformation based alignment (BCBA) 
 This method is followed when a known bioactive conformation of a     
compound is available as co-crystallized with the target structure. 
2) Conformational search conformation based alignment (CCBA) 
 In this method conformational search is performed with to observe the 
global minima.  Alignment is carried out with the global minima of all the 
compounds in the dataset.  
3) Docked conformation based alignment (DCBA) 
In this method the compounds are docked into the interacting domain of 
the target structure. 
4) Local minima confirmation based alignment (LCBA) 
Here the compounds are sketched and energy minimized to yield a local 
minima. The local minima conformation of each molecule in the database 
is used in the alignment procedure. 
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Rigid atom fit or field fit alignment are the most common types of 
alignment rules followed.  Both these alignment are performed keeping in 
mind that there is a minimum RMS deviation in the common points or 
atoms chosen in aligning the database.  The RMS deviation observed in 
the initial trial alignment of the dataset of the first forty two compounds 
was acceptable, but beyond compound forty (Cur_40) there is an 
observed significant root mean squares (RMS) deviation in the alignment 
of the molecules.  The degree of predictive properties of a three-
dimensional QSAR studies based on CoMFA and CoMSIA analysis are 
highly depends on extent of closeness in the common points chosen in 
aligning the database.  During the execution of the energy minimization 
protocol of each molecule, the compounds attain local energy minima.  
During this process the molecules assume a structure with the local 
minima energy conformation.  This local energy minimum varies from 
one molecule to the other in the dataset:  It depends on different atom 
types and varying substituents of the molecule. In three-dimensional 
QSAR studies, the alignment is the most important aspect to be 
considered to yield a better crossvalidated q2 (average r2) and eventually 
the predictions of the computational model. 
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          Thus, several methods and optimizations were carried out with the 
molecules to yield a best possible alignment.  Dihydral angles were 
modified for the analogs to achieve the desired configuration for the 
compounds that were not aligned properly when superimposed.  Two 
centroids (C1 and C2) were defined for the two aromatic substituents R1 
and R2.  The centroids C1 and C2 and all the atoms labeled 1, 2, 3, 4, 5 
and 6 of the central enone linker were chosen as common points in 
aligning the database.  The below figure shows the points chosen for 
alignment of the structures. 
                              X
X X
X
O
C1 C2
1
2
3
4
5
6
 
Fig 7.1  C1 and C2 centroids of the aromatic rings were done with the 
entire labeled atoms 1 trough 6 in the central chalcone bridge.  X 
represents various heteroatoms in the aromatic systems. 
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Fig 7.2 Initially developed trial alignment:  poorly aligned regions are 
seen in the central enone linker. 
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Fig 7.3  Rectified alignment: This alignment was achieved by atom fit of 
the central enone linker and the centroids C1 and C2 defined for Aromatic 
systems R1 and R2.  
 
Statistical analysis of the model: PLS (Partial Least Squares)  
 
          PLS (partial least squares) analysis in a statistical correlation 
analysis.29      PLS analysis is used with this dataset.  The natural logarithm 
of percentage inhibition, ln (% inhibition) is used as a dependent variable.  
The range of the dependent variable for the dataset is observed to be in a 
range of 5 log units. Steric and electrostatic field descriptors are used as 
the independent variable in three-dimensional QSAR CoMFA model 
development.  Similarly, five indices; electrostatic, steric, hydrogen bond 
donor, hydrogen bond acceptor and hydrophobicity indices are used as 
dependent variable in three-dimensional QSAR model development 
based on CoMSIA. 
 
PLS analysis with CoMFA descriptors 
        The dataset of sixty three compounds (Cur_1, Cur_2, up to Cur_63) 
was used in the analysis. Six compounds were not taken in the model 
development.  
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        The percentage inhibition for the compounds was observed to be 
zero at 3µg/ml. They are for compounds Cur_25, Cur_29, Cur_34, 
Cur_43, Cur_49, and Cur_56. The remaining compounds are fifty seven. 
This dataset was divided into,  training set of forty six compounds  ( 
Cur_1, Cur_2, Cur_3, Cur_4, Cur_5, Cur_6, Cur_8, Cur_9, Cur_10, 
Cur_12, Cur_13, Cur_14, Cur_15, Cur_16, Cur_17, Cur_18, Cur_19, 
Cur_20, Cur_22, Cur_23, Cur_24, Cur_26, Cur_28, Cur_30, Cur_32, 
Cur_33, Cur_35, Cur_36, Cur_37, Cur_39, Cur_40, Cur_41, Cur_42, 
Cur_44, Cur_45, Cur_47, Cur_48, Cur_51, Cur_53, Cur_54, Cur_55, 
Cur_57, Cur_58, Cur_60, Cur_62, Cur_63 ) and the remaining eleven 
compounds as the test set  
(Cur_7, Cur_11, Cur_21, Cur_27, Cur_31, Cur_38, Cur_46, Cur_50, 
Cur_52, Cur_59 and Cur_61) 
 
Table 7.1.  Training set - forty six compounds 
Cur_2 
 
Cur_3 
 
Cur_1 
 
Cur_4 
 
Cur_5
 
Cur_6 
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Cur_8 
 
Cur_9 
 
Cur_10 
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Cur_12 
 
Cur_13 
 
Cur_14
 
Cur_16 Cur_15
  
Cur_17 
 
Cur_18 
 
Cur_19 
 
Cur_2
 
Cur_23 
 
Cur_24 
 
Cur_22 
 
Cur_26 Cur_27 
 
Cur_28
 
Cur_30 
 
Cur_31 
 
Cur_32 
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Cur_33 
 
Cur_35
 
Cur_36 
 
Cur_37 
 
Cur_38 
 
Cur_39 
 
Cur_40 Cur_41 
  
Cur_42 
 
 
Cur_44
 
Cur_45 
 
Cur_46 
 
Cur_47 Cur_48 
 
Cur_50 
 
Cur_51 
 
Cur_52 
 
Cur_53 
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Cur_54 
 
Cur_55 
 
Cur_57 
 
Cur_58 
 
Cur_59 
 
Cur_60 
 
Cur_61 
 
Cur_62 
 
Cur_63 
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Table 7.2. Test set - Eleven compounds 
 
Cur_11 Cur_7 
 
 
Cur_21 
 
  
Cur_31 
 
 
Cur_38 
 
Cur_27 
 
Cur_46 
 
Cur_50 
 
Cur_52 
 
Cur_59 
 
Cur_61 
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Table 7.3.  Data set compounds not included in the QSAR study 
 
Cur_25 
 
Cur_29 
 
Cur_34 
 
Cur_43 
 
Cur_49 
 
Cur_56 
 
 
  
Developing a CoMFA region file 
          Since the model yielded a low cross validated q2, rotation of the 
training set alignment was carried out in an effort to see if this might 
increase the predictive property of the model.  The software creates the 
lattice and the lattice points based only on the initial alignment before the 
PLS run.  This is termed as the CoMFA region file.  The CoMFA region 
file has the dimensions in the x, y and z co-ordinates, the total number of 
lattice points, and the probe atom used to calculate the steric and 
electrostatic fields at the grid points.  This CoMFA region file with lattice 
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points is only a few angstroms from the most distant atom from the center 
of the common alignment.  As rotation of the alignment was carried out 
in the lattice, there is a possibility that the alignment shift beyond the PLS 
sampling lattice point, of the CoMFA region file.  To avoid an error of 
not sampling fields, a customized lattice (new region file) was created 
which is large enough in all the three-dimensions. To create this CoMFA 
region file, a few molecules from the original database were rotated 
orthogonal (perpendicular) to the common alignment. These new 
molecules have new co-ordinates, and the molecules were renamed and 
were put in the database.  The database has molecules with two different 
coordinates orthogonal to each other.  A new molecular spread sheet was 
created with the above database.  CoMFA columns were filled in the 
molecular spread sheet.  The newly created CoMFA region file was 
saved.   This saved CoMFA region file was used in the QSAR model 
after executing rotation and translation of the alignment of the training 
set. 
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          Dimension of the original CoMFA region file, the region file is 
created automatically while creating the CoMFA columns in the 
molecular spread sheet 
 
 Newly created CoMFA region file and its respective parameter 
 
 
In both the CoMFA region files, points indicate the number of lattice 
points. The lowest and higher corner indicate the total spacing in their 
respective dimensions (x, y and z coordinate axis) and the number of 
steps are the total steps in each co - ordinate.  Probe atom C. 3 is the sp3 
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hybridized carbon used in calculating the fields at the grid points. Charge 
1 indicates that the sp3 hybridized carbon has a charge of +1 
 
Table 7.4.  PLS statistical results for CoMFA and CoMSIA 3D-QSAR 
model 
        PLS details CoMFA COMSIA 
r2
0.213 0.183 
q2
0.239 0.146 
no validation r2
0.965 0.946 
S value 
0.190 0.236 
F value 
127.682 81.055 
Box Step size 
2 Å 2 Å 
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Column filter of 2.0 kcal/mole was used during the PLS analysis in both 
the CoMFA and CoMSIA QSAR model development.  Attenuation factor 
of  0.3 kcals/mole was used in the CoMSIA analysis.                                                       
                                                                  
 
Fig 7.4 CoMFA region file with the loaded alignment, the blue dots 
indicate the lattice points of the region file. 
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Table 7.5.  Results of the predictions of CoMFA and CoMSIA models 
Compounds Experimental 
CoMFA 
prediction 
CoMSIA 
Prediction 
CoMFA 
Residuals 
CoMSIA 
Residuals 
Cur_20 3.68 3.66 3.41 0.02 0.27 
Cur_1 4.53 4.09 4.15 0.44 0.38 
Cur_10 2.46 2.98 2.81 -0.52 -0.35 
Cur_11 4.47 3.45 4.61 1.02 -0.14 
Cur_12 3.2 3.25 2.93 -0.05 0.27 
Cur_13 4.32 4.28 4.10 0.04 0.22 
Cur_14 3.64 3.75 3.64 -0.11 0.00 
Cur_15 4.19 4.15 4.23 0.04 -0.04 
Cur_16 4.11 4.13 4.36 -0.02 -0.25 
Cur_17 3.93 3.99 3.92 -0.06 0.01 
Cur_18 3.78 3.77 3.94 0.01 -0.16 
Cur_19 4.03 4.03 4.00 0.00 0.03 
Cur_2 3.69 3.27 3.42 0.42 0.27 
Cur_21 3.90 3.34 3.62 0.55 0.28 
Cur_22 4.49 4.61 4.58 -0.12 -0.09 
Cur_23 3.46 3.52 3.45 -0.06 0.01 
Cur_24 3.98 4.14 4.17 -0.16 -0.19 
Cur_26 1.34 1.31 1.30 0.02 0.03 
Cur_27 4.48 4.26 3.03 0.22 1.45 
Cur_28 4.25 4.12 4.18 0.14 0.08 
Cur_3 4.59 4.17 4.11 0.42 0.47 
Cur_30 4.02 4.03 4.04 -0.01 -0.02 
Cur_31 4.37 0.79 2.17 3.56 2.20 
Cur_32 4.32 4.14 4.31 0.19 0.02 
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Cur_33 3.55 3.65 3.56 -0.10 -0.01 
Cur_35 2.56 2.54 2.50 0.013 0.06 
Cur_36 3.56 3.81 3.46 -0.25 0.11 
Cur_37 1.48 1.35 1.38 0.13 0.11 
Cur_38 1.63 1.56 1.50 0.07 0.13 
Cur_39 3.38 3.87 3.92 -0.49 -0.53 
Cur_4 2.34 2.51 2.55 -0.16 -0.22 
Cur_40 3.98 3.94 4.21 0.04 -0.23 
Cur_41 4.05 3.91 4.18 0.14 -0.13 
Cur_42 3.50 3.61 3.400 -0.11 0.10 
Cur_44 3.22 3.03 3.23 0.19 -0.02 
Cur_45 3.11 3.15 2.90 -0.04 0.21 
Cur_46 4.02 3.47 3.56 0.55 0.45 
Cur_47 3.19 3.09 3.30 0.09 -0.11 
Cur_48 0.37 0.37 0.41 -0.02 -0.04 
Cur_5 2.65 2.86 3.16 -0.21 -0.51 
Cur_50 2.67 1.11 1.92 1.56 0.75 
Cur_51 2.54 2.52 2.62 0.02 -0.08 
Cur_52 3.54 1.48 1.63 2.06 1.91 
Cur_53 3.48 3.39 3.67 0.07 -0.18 
Cur_54 3.79 3.97 3.91 -0.18 -0.12 
Cur_55 2.09 2.07 1.90 0.02 0.19 
Cur_57 4.05 4.11 4.18 -0.05 -0.12 
Cur_58 2.43 2.40 2.44 0.03 -0.01 
Cur_59 3.07 4.41 3.93 -1.34 -0.86 
Cur_6 4.06 4.20 3.96 -0.14 0.10 
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Cur_69 2.43 2.26 2.50 0.18 -0.07 
Cur_61 4.44 3.07 3.22 1.37 1.23 
Cur_62 3.61 3.84 3.92 -0.23 -0.31 
Cur_63 4.34 4.28 3.93 0.06 0.41 
Cur_7 4.21 3.43 3.54 0.78 0.67 
Cur_8 4.39 4.43 3.97 -0.04 0.42 
Cur_9 3.23 3.21 3.59 0.02 -0.36 
 
 
Fig 7.5  Scatter plot of CoMFA and CoMSIA analysis, predicted activity 
vs actual or experimental activity. The distribution of biological activity 
was observed to be in a range of five Log units. The points on the graph 
which are far away from the diagonal margin are considered to be 
outliers. 
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Affect of alignment on cross validated q2   for the derived QSAR 
model - Rotation of alignment in the lattice 
          To observe how the cross validated q2 is affected by the movement 
of the alignment of the training set compounds in the defined lattice; 
rotation of the alignment in the lattice was carried out.  Rotation of the 
alignment with the x-axis as the center of rotation was performed.  The 
STATIC ROTATE GLOBAL command was used via the Sybyl 
command line to execute this function in Sybyl.  The rotation was carried 
out in increments of 20 degrees from 0 to 180 degrees in a clockwise 
direction.  Since the lattice points of the CoMFA region file are 
orthogonal beyond 180 degrees, it is not necessary to carry additional 
rotation beyond 180 degrees because the PLS output will repeatedly be 
similar.  The PLS results indicate there is a significant affect of the 
molecular alignment in the Cartesian grid on the cross validated q2.   Such 
alignment affect in significantly low in CoMSIA as evident from the 
graph plotted, q2  vs angle of rotation; see Table 7.6 and Figure 7.6. 
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Angle of Rotation CoMFA q2 CoMSIA q2 
0 0.289 0.14 
20 0.197 0.13 
40 0.169 0.16 
60 0.128 0.101 
80 0.224 0.103 
100 0.212 0.115 
120 0.174 0.134 
140 0.234 0.094 
160 0.239 0.062 
180 0.106 0.148 
 
Table 7.6. Cross validated q2 observed in CoMFA and CoMSIA analysis 
with an incremental rotation in alignment. 
 
 
 
 
 
 
 
Fig 7.6 Cross validated q2 vs angle of rotation, it is evident here q2 value 
changes are minimum in CoMSIA analysis, where as in CoMFA analysis 
it is high. 
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CHAPTER VIII 
DEPENDENT VARIABLE TRANSFORMATION 
 
              Most QSAR studies are carried out using a standard biological 
response (Ki, IC50, LD50, or ED50).  These biological responses are 
produced with a varied concentration of the compounds in their 
respective biological affinity assay (experimental activity). Here in the 
curcumin analogs dataset the case is different, a varied biological 
response (percentage inhibition) produces for a defined concentrations 
(1µg/ml, 3µg/ml and 6µg/ml).  In a effort to transform the dependent 
variable i.e percentage inhibition (ranging from 0 to 100 %) to inverse 
Log10 ED50  (Log 1/ED50), this function is also termed as pED50 . The 
below is the method used to determine the pED50 of the dataset. The 
derived three different pED50 calculated for the three different 
concentrations were used as dependent variables in the QSAR model with 
the dataset, even with their transformed variable. The predictions of the 
model were not acceptable; the observed crossvalidated q2 observed was 
relatively low. 
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Essential of molecular pharmacology - The Saturation 
function23
Determination of  pED50: Negative Log10 ED50
   The determined pED50 values were used as dependent 
variables in CoMFA and COMSIA studies for the curcumin 
analog dataset.  
General form of the equation 
bx
x
a
y
+
=                                                                                             8.1 
x - concentration of a drug, ligand or substrate. 
y is a dependent variable, like amount of ligand bound, 
biological effect (IC50, LD50 or ED50 ) or velocity in enzyme 
kinetics:  Ki 
a - maximum value that corresponds to y 
When y is half maximal value then  
bx
x
a
y
+
== 5.0 , so x = b                                                           8.2 
For Receptor – Ligand Binding  
[ ]
[ ]
[ ]
[ ]DT KD
D
R
RD
B
b
+
==
max
                                                                                  8.3 
KD   - dissociation constant; ED50 
[RD] - receptor drug complex. 
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[R]T   - Total number of receptors. 
When KD = [D]  
max
0.5b
B
=                                                                                             8.4  
Fractional biological response (effect)   = % of maximal response
100
   8.5 
 (In our dataset, f = % Inhibition
100
)                                                        
max
Ef
E
= ; E is percent inhibition and E max is 100 %,                       8.6 
max
E
E
 is proportional to fraction of receptors occupied,  
[ ]
[ ]max T
RDb
B R
=                                                                                             8.7 
max
Ef
E
=  is proportional to α 
max
b
B
  (α is a proportionality constant). 
If C = Drug conc. 
max
b
B  =  DKC
C
+
       In this study C = Molarity (M)                 8.8 
Molarity was calculated by converting the micrograms per 
milliliter of the drug solution to their respective Molar 
strength (Molarity - M) 
DKC
Cf
+
=α                                                                                              8.9   
 f KD = α C – f C                                                                 8.10 
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f  = C  ⎟⎟
⎠
⎞
⎜⎜
⎝
⎛ −
DK
fα  
KD = C 
( )
f
f−α  
Here α is a proportionality constant, if α = 1 
KD  = C 
( )
f
f−1          8.11 
KD is the ED50
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Table 8.1. concentration c1, c2, and c3 are the concentration expressed in 
Molar strength: Molarity calculated for 1 µg/ml, 3 µg/ml and 6 µg/ml. 
percentage inhibitions are indicated as P1, P2 and P3 respectively. 
Molecule  
name 
Molecular 
weight C2 C1 C3 P1 P2 P3
Cur_7 236.31 12.70 4.24 25.39 36.3 67.3 89.5
Cur_61 284.36 10.55 3.52 21.10 84.7 84.9 78.8
Cur_3 291.18 10.30 3.43 20.61 73.7 98.2 98.1
Cur_1 208.26 14.40 4.80 28.81 71.6 92.8 94.4
Cur_40 308.38 9.73 3.24 19.46 54.6 53.5 71.3
Cur_41 358.44 8.37 2.79 16.74 52.5 57.3 48.1
Cur_13 346.04 8.67 2.89 17.34 48.3 75.3 93.7
Cur_6 236.31 12.69 4.23 25.39 47.7 57.9 89.6
Cur_28 253.26 11.85 3.95 23.69 47.6 70.3 84.5
Cur_14 238.29 12.59 4.20 25.18 43.5 38.1 69.1
Cur_11 276.26 10.86 3.62 21.72 42.3 87.4 96.9
Cur_8 236.31 12.69 4.23 25.39 41.7 80.4 87.3
Cur_22 209.25 14.34 4.78 28.67 40.7 89.1 96.9
Cur_51 268.27 11.18 3.73 22.37 36.5 12.7 24.5
Cur_21 328.36 9.14 3.04 18.27 36.2 49.2 39.2
Cur_53 253.26 11.85 3.95 23.69 33 32.5 68.9
Cur_62 303.19 9.89 3.30 19.79 32.8 37 53.7
Cur_19 268.31 11.18 3.73 22.36 31.8 56.4 60.8
Cur_27 388.16 7.73 2.58 15.46 31.1 88.6 88.6
Cur_52 252.27 11.89 3.96 23.78 31 34.3 80.8
 68
Cur_23 209.25 14.34 4.78 28.67 30.3 31.7 83.2
Cur_2 256.73 11.68 3.89 23.37 29.9 40.2 58.5
Cur_9 270.76 11.08 3.69 22.16 29.6 25.3 73.4
Cur_15 268.31 11.18 3.73 22.36 29.1 63.4 85.2
Cur_54 253.26 11.85 3.95 23.69 28.3 44.1 78.4
Cur_57 198.22 15.13 5.04 30.27 28.2 57.7 90.2
Cur_20 268.31 11.18 3.73 22.36 25.8 39.8 63.5
Cur_37 348.83 8.60 2.87 17.20 25.6 4.4 62.9
Cur_39 308.38 9.73 3.24 19.46 25.5 46.4 69
Cur_35 284.36 10.55 3.52 21.10 24.9 12.9 41.4
Cur_18 337.20 8.90 2.97 17.79 23.2 43.7 52.3
Cur_12 256.73 11.68 3.89 23.37 22.3 24.5 46.5
Cur_49 266.30 11.27 3.75 22.53 21.3 0.1 0.1
Cur_4 291.18 10.30 3.43 20.61 19.9 10.4 84.7
Cur_5 264.37 11.35 3.78 22.70 19.5 14.2 59.2
Cur_34 360.46 8.32 2.77 16.65 19.2 0.1 0.1
Cur_59 197.24 15.21 5.07 30.42 19 21.5 0.4
Cur_38 328.41 9.14 3.04 18.27 18.4 5.1 17
Cur_10 277.15 10.82 3.61 21.65 13.8 11.7 31.1
Cur_26 266.30 11.27 3.75 22.53 13.7 3.8 29.7
Cur_25 278.39 10.78 3.59 21.55 12.6 0.1 5.3
Cur_36 327.21 9.17 3.06 18.34 12.2 35.3 96.8
Cur_46 308.38 9.73 3.24 19.46 12 55.5 60.3
Cur_42 258.32 11.61 3.87 23.23 10.9 33.2 68.2
Cur_33 284.36 10.55 3.52 21.10 10.4 34.7 0.1
Cur_56 198.22 15.13 5.04 30.27 9.8 1.0 0.1
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Cur_58 197.24 15.21 5.07 30.42 8.3 11.4 19.4
Cur_55 188.18 15.94 5.314 31.88 7.7 8.1 12
Cur_30 298.21 10.060 3.35 20.12 6.6 55.6 88.7
Cur_48 302.33 9.92 3.31 19.85 5.7 1.4 11.9
Cur_60 234.30 12.80 4.27 25.61 5.7 11.4 40.8
Cur_16 277.15 10.82 3.61 21.65 4.6 61 94
Cur_17 277.15 10.82 3.61 21.65 2.2 51.1 88.7
Cur_47 312.32 9.61 3.202 19.211 1.9 24.2 48.1
Cur_24 210.24 14.27 4.76 28.54 0.1 53.4 85.2
Cur_29 298.21 10.06 3.35 20.12 0.1 0.1 0.1
Cur_31 258.32 11.61 3.87 23.23 0.1 78.7 88.6
Cur_32 258.32 11.613 3.87 23.23 0.1 75.4 66.2
Cur_43 408.5 7.344 2.45 14.69 0.1 0.1 4.7
Cur_44 308.38 9.73 3.24 19.46 0.1 24.9 50.3
Cur_45 308.38 9.73 3.24 19.46 0.1 22.4 52
Cur_50 282.29 10.63 3.54 21.25 1 14.4 45.5
Cur_63 284.36 10.55 3.52 21.10 1 76.4 52.1
 70
Table 8.1. f1, f2 and f3 and the derived pED50 for the three different 
concentrations. 
pED50 – 1: pED50   determined for 1µg/ml  
 pED50 – 2: pED50 determined for 3µg/ml 
pED50 – 3: pED50   determined for 6µg/ml 
STD: standard deviation 
Average pED50: Mean of pED50 - 1, pED50 - 2 and pED50  - 3 
 
  f1     f2     f3 pED50 -1 pED50 - 2 pED50 - 3     STD 
Average 
pED50
0.36 0.67 0.89 5.13 5.21 5.530 0.21 5.29
0.85 0.85 0.79 6.20 5.73 5.25 0.48 5.72
0.74 0.98 0.98 5.91 6.72 6.40 0.42 6.34
0.72 0.93 0.94 5.72 5.95 5.77 0.12 5.81
0.56 0.53 0.71 5.570 5.07 5.11 0.28 5.25
0.52 0.57 0.48 5.60 5.20 4.74 0.43 5.18
0.48 0.75 0.94 5.51 5.55 5.93 0.23 5.66
0.48 0.58 0.90 5.33 5.03 5.53 0.25 5.30
0.48 0.70 0.84 5.36 5.30 5.36 0.03 5.34
0.43 0.38 0.69 5.26 4.69 4.95 0.29 4.97
0.42 0.87 0.97 5.31 5.80 6.19 0.43 5.76
0.42 0.80 0.87 5.23 5.51 5.43 0.15 5.39
0.41 0.89 0.97 5.16 5.76 6.04 0.45 5.65
0.36 0.13 0.24 5.19 4.11 4.16 0.61 4.49
0.36 0.49 0.39 5.27 5.025 4.55 0.37 4.95
0.33 0.32 0.69 5.10 4.61 4.97 0.25 4.89
0.328 0.37 0.54 5.17 4.77 4.77 0.23 4.90
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0.32 0.56 0.61 5.10 5.06 4.84 0.14 5.00
0.31 0.89 0.89 5.24 6.00 5.70 0.38 5.65
0.31 0.34 0.81 5.05 4.64 5.25 0.31 4.98
0.30 0.32 0.83 4.96 4.51 5.24 0.37 4.90
0.299 0.40 0.58 5.04 4.76 4.78 0.16 4.86
0.30 0.25 0.73 5.06 4.48 5.09 0.34 4.88
0.29 0.63 0.85 5.04 5.19 5.41 0.19 5.21
0.28 0.44 0.78 4.00 4.82 5.18 0.18 5.00
0.28 0.58 0.90 4.89 4.95 5.48 0.32 5.11
0.26 0.40 0.63 4.97 4.77 4.89 0.10 4.88
0.26 0.04 0.63 5.08 3.73 4.99 0.76 4.60
0.25 0.46 0.70 5.02 4.95 5.06 0.06 5.01
0.25 0.13 0.41 4.97 4.15 4.52 0.41 4.55
0.23 0.44 0.52 5.01 4.94 4.79 0.11 4.91
0.22 0.24 0.46 4.87 4.44 4.57 0.22 4.63
0.21 0.00 0.00 4.86 1.95 1.65 1.77 2.82
0.20 0.10 0.85 4.86 4.05 5.43 0.69 4.78
0.19 0.14 0.59 4.81 4.16 4.82 0.37 4.59
0.19 0.00 0.00 4.93 2.08 1.78 1.74 2.93
0.19 0.21 0.00 4.66 4.25 2.12 1.37 3.68
0.18 0.05 0.17 4.87 3.77 4.05 0.57 4.23
0.14 0.12 0.31 4.65 4.09 4.32 0.28 4.35
0.14 0.04 0.30 4.63 3.54 4.27 0.55 4.15
0.13 0.00 0.05 4.60 1.97 3.41 1.32 3.33
0.12 0.35 0.97 4.66 4.77 6.22 0.87 5.22
0.12 0.55 0.60 4.62 5.11 4.89 0.24 4.87
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0.11 0.33 0.68 4.50 4.63 4.96 0.24 4.70
0.10 0.35 0.00 4.52 4.70 1.68 1.70 3.63
0.10 0.0 0.00 4.33 2.82 1.52 1.41 2.89
0.08 0.11 0.19 4.25 3.93 3.90 0.20 4.03
0.08 0.08 0.12 4.20 3.74 3.63 0.30 3.86
0.07 0.57 0.89 4.32        5.09 5.59 0.64 5.00
0.06 0.014 0.12 4.26 3.16 3.83 0.56 3.75
0.06 0.11 0.41 4.15 4.00 4.43 0.22 4.19
0.05 0.61 0.94 4.13 5.16 5.86 0.87 5.05
0.02 0.51 0.89 3.79 4.98 5.56 0.90 4.78
0.02 0.24 0.48 3.78 4.52 4.68 0.48 4.33
0.00 0.53 0.85 2.32 4.90 5.30 1.62 4.19
0.00 0.00 0.00 2.47 2.00 1.70 0.39 2.06
0.00 0.79 0.89 2.41 5.50 5.52 1.79 4.48
0.00 0.75 0.66 2.41 5.42 4.93 1.61 4.25
0.00 0.00 0.05 2.61 2.13 3.53 0.71 2.76
0.00 0.25 0.50 2.49 4.53 4.72 1.24 3.91
0.00 0.22 0.52 2.49 4.47 4.75 1.23 3.90
0.01 0.14 0.45 3.45 4.20 4.59 0.58 4.08
0.01 0.76 0.52 3.46 5.49 4.71 1.02 4.55
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CHAPTER IX 
RESULTS AND DISCUSSIONS 
 
          Curcumin and several of its structural analogs have a diverse range 
of activity towards various mediators of cancer progression.  Selectivity 
is an important factor. Initial pharmacophore perception in MOE 
(Molecular Operating Environment) results in the identification of the 
interaction pharmacophore elements: IPEs.  There are two aromatic 
systems: F3-Ar1 and F4-Ar2 as well as a hydrogen bond donor - F1 and a 
hydrogen bond acceptor - F2, see figure 9.1. The pharmacophore model 
developed is a four point pharmacophore model.  These interacting 
pharmacophore elements (F1, F2, F3 and F4) are imperative for biological 
activity. The spacing of the pharmacophore elements was indicated in the 
Figure 9.1. This pharmacophore was used as a search query in the 
screening of the National Cancer Institute (NCI) database of 21607 
compounds.  After successfully screening the NCI database, 1471 
compounds were identified as hits.  These hits can be further filtered with 
Lipinski’s Rule of Five.24 The rule determines the essential features for a 
drug-like molecule, even though a molecule might be highly potent if it 
violates the Lipinski’s Rule of Five, it is unlikely, but not absolutely 
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guaranteed, that the molecule cannot be developed to a future clinical 
candidate. 
 
 
 
 
 Fig 9.1.  Four point pharmacophore hypothesis of aromatic enones with 
spacing between the pharmacophore elements. F3 and F4 are the aromatic 
systems, F2 is the Hydrogen bond donor and F1 is the hydrogen bond 
acceptor. 
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         Information related to biological target specific binding of curcumin 
analogs is lacking.  Thus, ligand based modeling is the best available 
option.  Three-dimensional QSAR analysis is one of the most reliable 
methods in ligand based computational model development.  
 
Initially when all the sixty-three structures were taken collectively 
in model building, the statistical results of the PLS runs were not good. 
The convergent r2 was approximately in a range of 0.08 magnitude of the 
fifty seven compound dataset.  When grouping the dataset into the 
training and test sets, no correlation was identified in the training set 
between the molecular field descriptors and the dependent variable 
(natural log function of percentage inhibition at 3µg/ml concentration).  
           
Usually three-dimensional QSAR studies are carried out with 
standard biological response (IC50, LD50, ED50, Ki - which is converted to 
an inverse Log function) observed at a defined concentration of each 
compound in the cell based assay study.  In the present biological assay it 
is different, a varied biological response (percentage growth inhibition) at 
a defined concentration (three different concentrations). So a 
pharmacodynamic conversion was derived with the available two 
variables (percentage inhibition and concentration of the drug solution) 
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into ED50 and the negative log function (pED50) is taken as the dependent 
variable in the QSAR model development. Even with effort an acceptable 
correlation was achieved with the model. When six compounds Cur_25, 
Cur_29, Cur_34, Cur_43, Cur_49, and Cur_56 were eliminated from the 
training set, there is a correlation observed in the model. The 
crossvalidated q2 for CoMFA was 0.289 and 0.146 in CoMSIA analysis.  
The results and the outcomes of this final QSAR model are acceptable, 
which is evident in the final validation of the model with the prediction 
set compounds and the contour maps.  The feature present in the 
molecule complements the QSAR contour maps of the model. Standard 
deviation method is used in deriving the contour maps. 
 
           A few compounds with good prediction in the training set and the 
test were placed in the contour maps.  The predictions of the derived 
three- dimensional QSAR model were acceptable. When few compounds 
of the training set and the test set were chosen to validate the model, the 
molecular features were observed.  By visualizing them in the QSAR 
contour maps, there is a compatibility observed in the predictions. 
Therefore, with structural modification with different functional groups 
and their respective orientation in three-dimensional space might result in 
increased activity of the molecules as evident with the contour maps. 
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Fig 9.2.  CoMFA stereo view contour coefficient maps, Cur_26, is placed 
in the three dimension contour map. 
 
                              CoMFA contour maps color codes 
Interaction fields Green Yellow 
Steric Favors interaction Disfavors interaction 
Electrostatic Blue favors positively 
charged group 
interaction 
Red favors negatively 
charged group 
interaction 
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Figure 9.3.  CoMSIA stereo view, the upper right corner has the scatter 
plot of the training set compounds Cur_11, a test set compound placed in 
the CoMSIA contour map. 
 
CoMSIA contour coefficient map color codes 
Interaction Fields Favor interaction Disfavor interaction 
Steric Green Yellow 
Electrostatic Blue Red 
Hydrophobicity Yellow White 
Hydrogen bond 
acceptor 
Magenta Red 
Hydrogen bond donor Cyan Purple 
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           The contour maps shown below indicate the individual CoMSIA 
field contributions and their corresponding stereo view. Some of the 
training set and test set compounds were placed in the contour coefficient 
maps for qualitative inspection for identification of various groups that 
favor and disfavor interaction and their contribution towards activity. 
 
 
 
 Fig 9.4.  CoMSIA steric and electrostatic contour map with the total 
dataset alignment. 
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           Green indicates steric interactions are favorable in the regions and 
yellow indicates it is disfavored.  For electrostatic interactions, blue 
indicates positively charged groups are favored in the region and red 
indicates negatively charged groups are favored. 
     
 
Contour details 
Steric green – 92.00 and yellow – 20.00 
Electrostatic blue – 91.00 and red – 18.00 
Fig 9.5.  Steric and Electrostatic contour maps. Training set compound 
cur_11 
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Steric: Green indicates steric interactions are favored in the region and 
yellow indicates it is disfavored.  
Electrostatic: Blue indicates positively charged electrostatic interactions 
are favored in that region and red indicates it is disfavored.   In the map 
there is a triflouro group present on R2 aromatic system, which is a strong 
prediction of the model. 
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Contour details 
Magenta - 80 
Red - 15 
Fig 9.6. Training set compound cur_9 
 
HYDROGEN BOND ACCEPTOR SYSTEM  
Magenta indicates H-bond acceptor groups are favored in the region of 
the molecule.  Magenta - 80 
Red indicates H-bond acceptor groups are disfavored in that region. 
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Contour details 
Yellow – 87.00 
White – 10.00 
 
Figure 9.7. Test set compound Cur_11 
Hydrophobicity: yellow indicates hydrophobic group are favored in the 
region and white indicates it is disfavored. 
 
 85
 
Contour details 
Cyan – 95.00 
Purple – 56.00 
Fig 9.8. Training set compound cur_59 
Hydrogen bond donor system 
 Cyan indicates hydrogen bond donor groups are favored in that region 
and purple indicates hydrogen bond donor groups are disfavored in the 
region.  
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CHAPTER X 
FUTURE RESEARCH 
 
          Curcumin is considered as an important lead candidate in 
biochemical research as evident from various sources.  As its activity 
profile is not unique to only a specific target or to a class of closely 
related biological targets, future research should be focused to identify all 
the targets to which curcumin exhibits its affinity/inhibition potential. In 
silico and computational research methods can be feasible if the structural 
data of the targets are reported.  These are usually reported as a co-crystal 
structure of the biological target with the ligand bound to the active 
domain or a NMR data of the putative target.  The ligand can be 
curcumin or compounds that have some degree of structural resemblance 
with curcumin.  Solubility is a major hurdle for the development of 
curcumin or its structural analogs. These factors need to be taken into 
account in future research that focus on the design and synthesize of 
compounds that have greater water solubility. 
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